Tag: "affymetrix" at biology news

Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering

Sacramento - Today, Affymetrix, Inc..announced plans to make eight new GeneChip(R) plant and animal genome.arrays available in 2005 as part of its Consortia Program, including.canine, Rhesus macaque, Medicago trancatula (legume), Brassica, tomato,.citrus, poplar and sugar cane. More than 20 research presentations at.this week's Plant and Animal Genome Conference XIII in San Diego,.Calif. feature...

New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Scientists at Affymetrix, Inc. (Nasdaq: AFFX) reported today in Science magazine online that they have completed a high-resolution scan of structure and function for nearly 30 percent of the human genome sequence. In collaboration with the National Cancer Institute, the research team used high-density GeneChip(R) microarrays to study every fifth base, on average, of 10 human chromosomes; they fou...

Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance

Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska Institutet announced today that they have entered into a strategic alliance designed to improve healthcare by accelerating the translation of basic genetic research into tools for better diagnosis, prognosis, and treatment. .. During the next five years the projects include genetic analyses and measurement of gene expression in patients with at...

Affymetrix and Stratagene Announce Strategic Software Alliance

. In April 2005, Affymetrix will make ArrayAssist Li...

Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences

Caliper Life Sciences, Inc. (Nasdaq: CALP) and Affymetrix, Inc. (Nasdaq: AFFX) today announced that Caliper has issued Affymetrix a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip(R) microarray technologies. The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnosti...

Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX

Affymetrix Inc. (Nasdaq: AFFX), announced today the launch of the new GeneChip(R) Globin-Reduction kits and associated protocol developed in conjunction with PreAnalytiX -- a joint venture between QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company). The new kits optimize the PreAnalytiX PAXgene(TM) Blood RNA System for use with Affymetrix GeneChip tec...

Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics

Affymetrix Inc. (Nasdaq: AFFX) and bioMerieux announced today that Affymetrix has granted bioMerieux long-term and comprehensive access to its GeneChip(R) technology to develop and market in vitro diagnostic tests for breast cancer, as well as an option to expand the agreement into other cancer areas. . .. "Microarrays are o...

Affymetrix and ParAllele Launch Industry's Most Comprehensive Product Line for Targeted Genotyping

Twenty-eight years after intense selective logging stopped in the region now known as Uganda's Kibale National Park, the red-tailed guenon (Cercophithecus ascanius) is a primate still in decline. The logging practice, scientists report in a new study, changed the ecological balance for these monkeys, leading to behavioral changes and opening the door for multiple parasitic infections. . The resea...

Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible . .. The Genomatix line of products which achieved Gene...

Affymetrix 500K array used to identify memory gene

Affymetrix Inc. announced today that researchers at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona have used the Affymetrix 500K Array to discover a gene--called Kibra--associated with memory performance in humans. The team's findings may be used to develop new medicines for memory-based diseases such as Alzheimer's and Parkinson's by providing scientists with a better u...